SCHEMBL6089609

SCHEMBL6089609

CCCCC(=O)Nc1c(C(=O)O)n(Cc2cccc(Cl)c2)c2cc(-c3ccc(C(F)(F)F)cc3)ccc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGES O14684 1/20 0.42
THRB P10828 1/20 0.41
GRIN1 Q05586 1/20 0.41
GRIN2B Q13224 1/20 0.41
TP53 P04637 1/20 0.40
GSK3B P49841 3/20 0.40
KCNQ3 O43525 1/20 0.40
KCNQ2 O43526 1/20 0.40
KCNQ4 P56696 1/20 0.40
KCNQ5 Q9NR82 1/20 0.40
EGLN1 Q9GZT9 2/20 0.38
EGLN2 Q96KS0 1/20 0.38
EGLN3 Q9H6Z9 1/20 0.38
PLA2G2A P14555 1/20 0.38
ALDH1A1 P00352 2/20 0.38
MAPT P10636 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
FFAR2 O15552 1/20 0.37
KDM4E B2RXH2 1/20 0.37
SERPINE1 P05121 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6091492 0.93 THRB (0.43) PTGESTHRBGRIN1GRIN2BTP53
SCHEMBL6089685 0.88 GRIN1 (0.44) PTGESTHRBGRIN1GRIN2BTP53
SCHEMBL6091451 0.86 SLC2A1 (0.44) PTGESGRIN1GRIN2BEGLN1EGLN2
SCHEMBL6091691 0.85 TP53 (0.44) PTGESTHRBTP53GSK3BPLA2G2A
SCHEMBL6091172 0.84 TP53 (0.41) PTGESTHRBTP53GSK3BALDH1A1
SCHEMBL5747009 0.84 THRB (0.45) THRBTP53GSK3BSERPINE1
SCHEMBL6091368 0.82 GRIN1 (0.43) PTGESGRIN1GRIN2BEGLN1EGLN2
SCHEMBL6091756 0.82 GRIN1 (0.40) PTGESGRIN1GRIN2BEGLN1EGLN2
SCHEMBL6092174 0.81 THRB (0.44) PTGESTHRBTP53GSK3BPLA2G2A
SCHEMBL6092963 0.80 TP53 (0.43) PTGESTHRBTP53GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160879-A1 Indoles useful in the treatment of inflammation BIOLIPOX AB (SE) 2006-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160879-A1 Indoles useful in the treatment of inflammation IDO1, PTGS1, IDO2 PTGES 4/4885THRB 1146/4885GRIN1 1424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.